ASMB
Assembly Biosciences, Inc.
ASMB has the edge over NVO overall, supported by stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
ASMB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
ASMB's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ASMB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $19.00 | -5.8% |
| Current | 20x | $20.18 | — |
| Fair | 124x | $124 | +513% |
| Expensive | 344x | $344 | +1604% |
Historical ranges are pointers, not guarantees.
ASMB's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ASMB in the historical PE scenario, which offers more potential upside but is not a forecast.
ASMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ASMB's losses to shrink, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ASMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.00 | +$5.76 |
| Q2 2026 | $1.21 | +$6.76 |
| Q1 2026 | $0.08 | +$6.28 |
| Q4 2025 | -$0.55 | +$6.14 |
| Q3 2025 | -$4.76 | +$2.25 |
| Q2 2025 | -$5.55 | +$3.19 |
| Q1 2025 | -$6.20 | +$4.40 |
| Q4 2024 | -$6.69 | +$6.69 |
ASMB has returned to profit: it earned $1.00 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ASMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3M | -73% |
| Q2 2026 | $13.4M | +39% |
| Q1 2026 | $8.2M | -13% |
| Q4 2025 | $42.5M | +477% |
| Q3 2025 | $10.8M | +58% |
| Q2 2025 | $9.6M | +13% |
| Q1 2025 | $9.4M | +63% |
| Q3 2021 | $6.3M | -82% |
ASMB's revenue is growing: $3M last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -792% | -691 points |
| Q2 2026 | -47% | +68 points |
| Q1 2026 | -138% | -33 points |
| Q4 2025 | 47% | +203 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -115% | +28 points |
| Q1 2025 | -106% | +80 points |
| Q4 2024 | -157% | N/A |
ASMB's operating margin was −792% last quarter, down 691 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ASMB on profitability, with a higher operating margin.
ASMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.3M | -$2.1M |
| Q2 2026 | -$15.5M | +$1.3M |
| Q1 2026 | -$22.1M | +$1.3M |
| Q4 2025 | $14.2M | +$14.6M |
| Q3 2025 | -$15.2M | +$69K |
| Q2 2025 | -$16.8M | +$358K |
| Q1 2025 | -$23.4M | -$5.1M |
| Q4 2024 | -$407K | -101% |
ASMB has burned cash in almost every quarter: −$41M over the past year, against −$56M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ASMB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASMB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +2.9M shares |
| 1 year | +184% | +14.1M shares |
| 3 years | +400% | +17.4M shares |
| 5 years | +510% | +18.2M shares |
| Available history | +895% | +19.6M shares |
ASMB has 22M diluted shares, up 184% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ASMB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ASMB Net Leverage
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ASMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 5.7 | Oversold |
ASMB's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ASMB PE vs Healthcare Sector
| Metric | ASMB | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 26x | 22% below |
| PE % | 26 | 29 | 3 pts below |
ASMB is trading at 20x earnings, a 22% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ASMB on valuation relative to its sector.
ASMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.3 | 5.3% below |
| 20 week MA | $26.1 | 23% below |
| 50 week MA | $27.8 | 27% below |
| 100 week MA | $23.4 | 14% below |
| 200 week MA | $18.4 | 9.9% above |
ASMB has fallen below most of its moving averages, though it's still 9.9% above its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ASMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $251.3 | $74.4 | -70% |
| 2021 | $74.4 | $27.2 | -63% |
| 2022 | $27.2 | $15.1 | -44% |
| 2023 | $15.1 | $9.84 | -35% |
| 2024 | $9.84 | $15.2 | +54% |
| 2025 | $15.2 | $33.6 | +122% |
| 2026 YTD | $33.6 | $20.2 | -40% |
ASMB's yearly returns have swung widely, from +122% in 2025 to −70% in 2020. It's down 40% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ASMB on returns for 2026, with the stronger performance.